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Abstract
The objective of this study was to evaluate medication adherence, medical services utilization, and combined
medical and pharmacy expenditures associated with diabetes and hypertension value-based insurance design
(VBID) plus health/disease coaching programs implemented by a large employer. A pre/post participant versus
nonparticipant study design was used to measure medication possession ratios (MPRs), inpatient admissions,
emergency room utilization, and combined medical and pharmacy expenditures for employees/spouses with
diabetes (n= 1090; average 23 months follow-up) and hypertension (n = 3254; average 13 months follow-up)
participating in a VBID plus health/disease coaching relative to eligible nonparticipants. Outcome measures
were propensity score weighted and regression adjusted to estimate the independent impact of the programs.
MPRs for diabetes and hypertension were significantly increased 3 to 4 percentage points for VBID partici-
pants, while MPRs for respective nonparticipants decreased by about 10 percentage points. Employer-paid
pharmacy expenditures increased significantly for both participants with diabetes and hypertension while out-
of-pocket patient co-payments decreased significantly. Medical expenditures for diabetes VBID participants
decreased but not significantly. Hypertension participants experienced medical expenditure increases. Medical
services utilization of inpatient admissions and emergency room visits underwent minimal change. Thus
employer-sponsored diabetes and hypertension VBID plus health/disease coaching programs can be expected to
lower patient co-payments and significantly increase medication adherence. Meanwhile, medical spending
outcomes indicated that increased diabetes and hypertension pharmacy expenditures were partially offset by
medical savings (for diabetes) but not sufficiently to be cost neutral. (Population Health Management
2015;18:151–158)
Introduction
Value-based insurance designs (VBIDs) have beenused to improve quality of care, encouraging improved
adherence to pharmaceutical protocols by selectively lowering
patients’ out-of-pocket medication spending. Generally, VBID
programs provide reduced prescription drug co-payment
costs for target chronic conditions such as diabetes,1–10 hy-
pertension,1,6–10 hyperlipidemia,6,8–13 and asthma.1,7,10 VBID
programs have been implemented successfully in both health
plan3,5,8,9,13 and employer markets.1,2,4,6,7,10–12
In recent years, consumer prescription drug price sharing
and co-payment levels have increased steadily. The unin-
tended consequence of these strategies was that as patient
co-payments increased, medication adherence decreased. Ac-
cording to one meta-analysis, it was estimated that for every
10% increase in cost sharing, prescription drug spending
decreased by 2% to 6%.14 In another study, every $10 in-
crease in patient cost sharing resulted in a 5.4% reduction in
adherence to oral diabetic medications.15 Of clinical impor-
tance, it has been demonstrated that medication nonadherence
was associated with documented adverse outcomes (eg,
higher blood pressure, higher HbA1c levels among patients
with diabetes, increased rates of diabetic complications, higher
low-density lipoprotein cholesterol levels).15–17 Meanwhile,
improved medication adherence was associated with fewer
complications, lower medical spending, fewer emergency
room visits, lower all-cause hospitalization rates, and lower
all-cause mortality rates.14–16,18
Large employers have been experimenting with various
VBID models for some time—the most notable of these being
Pitney Bowes. Its VBID program was systematically designed
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and subsequently evaluated to measure improved medication
adherence for 2 selected drug classes (ie, cholesterol-
lowering statins; clopidogrel, a blood clot inhibitor).10,11,19
Contrary to traditional insurance designs that price medi-
cations to the consumer based on their purchasing costs,
VBID programs lower cost sharing for selected high-value
medications with evidence-based outcomes. In a recent
Mercer report,20 about 23% of large (500 + ) employers in-
dicated currently using VBID programs with 27% planning
to use them in the future.
Although these plans are growing in popularity, currently
no standard approach to VBID programs exists. There are
variations in the chronic conditions targeted1–10 and, com-
monly, programs reduce selected generic drug co-payments
to $0 and reduce co-payments for other preferred/non-
preferred brand name drugs.5,6,8–10 However, other pro-
grams reduce coinsurance co-payment percentages based on
established drug costs (eg, 10% of prescription cost from
20% to 50% coinsurance rates)1,2,7 or reduce co-payments to
flat rates (eg, $10 flat co-payment).3,4 More recently, some
VBID programs have begun to include disease management
coaching.2,6,10
A recent review of VBID programs21 concluded that VBID
programs are generally successful in improving quality of
care by increasing adherence to medication protocols. How-
ever, the expected program impact of reduced medical
spending has been less well documented. The general con-
sensus across several studies was that VBID programs were
cost neutral,1,2,6,12,21,22 generating sufficient medical savings
to offset increased prescription drug spending.21
Because of employers’ continued interest in the im-
plementation of VBID models, the research team undertook
the evaluation of a newly introduced diabetes and hyper-
tension VBID program at a large employer. The purpose of
the study was to evaluate the impact of the VBID program
design plus health/disease coaching on medication adher-
ence, medical services utilization, and medical and phar-
macy expenditures. Key outcomes included comparisons of
participants and nonparticipants with respect to: (1) medi-
cation possession ratios (MPRs), (2) utilization rates for
inpatient admissions and emergency room visits, and (3)
combined medical and pharmacy expenditures.
Methods
Study design
This study utilized a pre/post participant and nonpartici-
pant comparison group design to evaluate a diabetes and
hypertension VBID plus health/disease coaching program
implemented by a large employer. The diabetes program
initiated in 2010 utilized a baseline period 3 to 12 months
prior to the enrollment date with 3 to 36 months (average 23
months) of follow-up through June 2013. The hypertension
program initiated in 2011 utilized similar baseline criteria
prior to the enrollment date and 3 to 24 months (average 13
months) of follow-up through June 2013.
Participation in the program was documented with en-
rollment dates and from payments made by the pharma-
ceutical benefit management (PBM) provider. Eligible
nonparticipants must have used at least 1 prescription within
the respective therapeutic classes or had at least 2 diagno-
sis codes to confirm the target diagnosis. The difference-
in-difference (DID) design compared pre to post defined
medication adherence and medical spending outcomes for
VBID participants and nonparticipants.
Sample
Employees and spouses enrolled in lifestyle management
health coaching or disease management coaching programs
who had been diagnosed with either diabetes or hyper-
tension were eligible for the VBID programs. The lifestyle
management and disease management programs were part
of a broader corporate health management program. Eligible
VBID participants and nonparticipants must have had at
least 3 months of continuous medical plan enrollment prior
to their enrollment date and at least 3 months of continuous
enrollment after enrollment (ie, a minimum of 6 months of
continuous medical enrollment).
To better understand the costs associated with patients
who regularly use pharmaceuticals to manage their condi-
tion (ie, chronic pharmacy utilizers), the research team im-
plemented an additional criterion that VBID participants and
nonparticipants must have had at least 2 prescriptions in the
pre and post time periods within the respective therapeutic
classes. Outliers were removed to equalize the total health
care and pharmacy expenditure distributions between par-
ticipants and nonparticipants in the pre and post periods,
resulting in the exclusion of 3% of observations. Maternity
cases also were excluded. The final study populations in-
cluded 814 diabetes VBID employee/spouse participants
and 276 diabetes nonparticipant controls and 2674 hyper-
tension VBID participants and 580 hypertension nonpartic-
ipant controls. Study groups were not mutually exclusive,
thus allowing individuals to be enrolled in either or both of
the chronic condition programs.
VBID plus health/disease coaching program
Eligible VBID participants and nonparticipants must
have been currently enrolled in either lifestyle management
or disease management coaching programs and referred to
the VBID program by the respective health/disease coaches.
Coverage for diabetic and hypertension medications and
diabetic supplies were made available with reduced or elim-
inated co-payments. Similar to other plans, generic drug co-
payments were eliminated (ie, $0). Preferred brands were
available with $5 co-payments for a 34-day supply or $15
for a 90-day supply. Non-preferred brands were available at
50% coinsurance rates with applicable minimum/maximum
levels. Diabetic supplies were made available at no cost to
members with diabetes.
Measures
Outcome measures. Key outcome measures for this
evaluation included pre/post comparisons of: (1) MPRs,
(2) medical services utilization (ie, inpatient admissions,
emergency room visits), and (3) combined medical and
pharmacy expenditures for participants and nonparticipants,
respectively.
Medication possession ratios. Medication adherence
was defined as MPRs based on the percentage of days that a
member had his or her medication available over the pre
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period and the subsequent time enrolled in the program. The
dates when prescriptions were filled and the number of days’
supply on the prescription drug claims were used to deter-
mine how many days medications were on hand. The re-
search team calculated the ratio as a combined metric for all
drugs prescribed within a therapeutic class. Post period re-
sults are presented as 2-year averages for participants with
diabetes and as a 1-year average for those with hyper-
tension. Use of electronic pharmacy records to determine
medication adherence and/or nonadherence have been pre-
viously validated comparing patient reports, pharmacy re-
cords, and pill counts to verify pharmacy records.23
Medical services utilization. All-cause medical services
utilization rates for inpatient admissions and emergency
room visits were calculated from place of service codes
within medical claims. Emergency room visits and inpatient
admission utilization rates were calculated for the pre pe-
riod prior to enrollment and for the follow-up post periods
for participants and nonparticipants with diabetes and hy-
pertension, respectively. Because baseline and follow-up
periods could be variable, rates were annualized for partic-
ipant and nonparticipant comparisons (ie, total inpatient or
emergency room events divided by the total member years).
Health care and pharmacy costs. Health care expendi-
tures (per member per month [PMPM]) were calculated in
US dollars for each eligible employee and spouse, including
all inpatient, outpatient, professional, and pharmacy paid
claims, for at least 3 months and up to 12 months prior to the
enrollment date and for at least 3 months and up to 36
months (diabetes) or 24 months (hypertension) after the en-
rollment date. All costs were adjusted to 2013 dollars using
the medical care services component in the Consumer Price
Index. Employer-paid claims were used to provide medi-
cal and pharmacy expenditure trend outcomes, enabling the
employer to assess potential medical savings relative to the
investment in additional pharmacy coverage. Pharmaceu-
tical co-payments for participants and nonparticipants were
calculated separately to document changes in patient co-
payments after enrollment in the VBID program.
Covariates. Covariates were included to adjust for other
factors that may influence the selection bias often associ-
ated with program participation. These covariates included
measures of demographics, health status, and other charac-
teristics taken from health plan eligibility and claims files.
Demographic variables included the participant’s age, sex,
and location. Age was stratified into 4 groups (age: 18–34,
35–44, 45–54, and 55+ years). Insurance plans included:
Blue Cross Blue Shield, Aetna, UnitedHealthcare, and Other.
Income and location were geocoded from zip codes to:
High, Upper Medium, Lower Medium, and Low for income;
Metropolitan and Other for location. The number of avail-
able months in the pre and post periods were added to ac-
count for different lengths of time in the programs.
Health status covariates were measured from claims data
and included the calculated Charlson Comorbidity Index
(CCI),24 Psychiatric Diagnostic Group score (PDG),25 and
the annual number of physician office visits, emergency
room visits, and inpatient admissions. The CCI is a measure
of the risk of 1-year all-cause mortality attributable to se-
lected comorbidities that also has been shown to be highly
predictive of morbidity and health care expenditures. The
PDG score includes validated psychiatric diagnostic groups
analogous to major diagnostic groups in the diagnostics-
related group system but provides better classification of
individuals with substance abuse and/or mental health dis-
orders. Measures of health services availability included:
acute hospital beds per 1000 and primary care physicians
per 100,000. Differences in covariates between partici-
pants and nonparticipants were tested with chi-square tests
for categorical variables or Student t tests for continuous
variables.
Statistical analyses
Propensity score weighting. Propensity score weighting
used information about the demographic, socioeconomic,
and health status variables already described to adjust for
potential selection bias often associated with participation
in programs, thereby allowing the comparison of partici-
pants to similar nonparticipants. This information was used
to estimate the underlying probability of VBID program
participation for each individual. The research team then
used that estimated probability to create a weighting vari-
able applied to the data from those who chose not to par-
ticipate in the programs, to make them better resemble all
eligible employees/spouses. The value of the weighting var-
iable equals 1/predicted probability of specific program par-
ticipation. The utility of propensity score models to adjust
for external validity threats are described elsewhere.26,27
Regression modeling. After propensity score weighting,
statistical differences between diabetes and hypertension
VBID program participants and nonparticipants are expected
to be minimized or eliminated. Any remaining differences,
however, were subsequently adjusted for using generalized
linear regression models as a final adjustment in comparing
the outcome variables as reported elsewhere.28 Differences
in the weighted outcome measures (ie, medical expendi-
tures, MPRs, utilization measures) between participants and
nonparticipants (ie, DID) thus controlled for demographics,
health status, and health plan characteristics.
Results
Take-up rates for the VBID programs were very high
among those chronic pharmacy utilizers identified for the
evaluation: 75% of those with diabetes and 82% of those
with hypertension. Baseline characteristics of participants
and nonparticipants in the diabetes and hypertension VBID
programs are shown in Tables 1 and 2. Participants in the
diabetes and hypertension programs were less healthy than
their respective nonparticipant controls (eg, higher CCI scores,
higher medical utilization), further documenting the need
for propensity score weighting. The weighting worked well,
as the significant differences between participants and re-
spective nonparticipant controls were generally removed or
minimized as illustrated in Table 1 and Table 2, respec-
tively. Because some case-mix differences still remained
between the groups, subsequent regression adjustments were
warranted to further minimize these differences.
Comparisons of descriptive unadjusted MPRs for partic-
ipants with diabetes indicated that medication adherence
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improved by 4 percentage points for participants while
medication adherence for nonparticipants decreased by
about 10 percentage points, as illustrated in Figure 1. Si-
milarly, MPRs for participants with hypertension increased
by about 3 percentage points and decreased for nonpartici-
pants by about 9 percentage points. Regression-adjusted
weighted DIDs for MPRs comparing participant and non-
participant trends indicated a significant 14.1 percentage
point gain for participants with diabetes (P < 0.0001) and a
significant 14.3 percentage point gain for participants with
hypertension (P < 0.0001) as illustrated in Tables 3 and 4,
respectively.
Adjusted health care expenditures for participants with
diabetes indicated significantly increased pharmacy costs
relative to nonparticipants (P< 0.0001) and small but non-
significant savings in medical costs (P = 0.58), as shown in
Table 3. Overall, although savings in medical expendi-
tures for participants with diabetes partially offset increased
pharmaceutical payments, those savings were not sufficient
for the program to be considered cost neutral. However,
adjusted combined medical and pharmacy expenditure DIDs
comparing participants and nonparticipants were not sta-
tistically significant (P= 0.48). Participants with diabetes,
meanwhile, experienced significant co-payment reduc-
tions: $20.60 savings per month or about $250 per year
(P < 0.0001; data not shown). Annualized adjusted differ-
ences for inpatient admissions and emergency room utili-
zation rates for participants with diabetes indicated no
Table 1. Baseline Characteristics of Diabetes VBID Participants and Nonparticipants
Before and After Propensity Score Weighting
Unweighted Propensity Score Weighted
Participant Nonparticipant Participant Nonparticipant
Mean or % Mean or % P value Mean or % Mean or % P value
814 276 814 276
Age (average age) 49.6 47.4 0.001 49.0 49.3 0.69
18–34 6.5 7.3 0.001 6.5 6.1 0.99
35–44 23.1 33.7 25.5 25.2
45–54 36.0 36.2 36.3 37.2
55+ 34.4 22.8 31.7 31.6
Sex
Female 36.1 36.6 0.88 35.8 33.8 0.55
Male 63.9 63.4 64.2 66.2
Relationship
Employee 80.8 80.8 0.99 80.6 84.1 0.20
Spouse 19.2 19.2 19.4 15.9
Health plan
Aetna 41.2 45.3 0.0001 42.5 42.3 0.19
BCBS 31.6 22.1 30.0 34.5
UHC 23.7 23.6 23.2 17.7
Other 3.6 9.1 4.4 5.6
Income
High 66.2 64.5 0.41 65.4 65.3 0.16
Upper Medium 15.7 15.6 16.0 15.6
Lower Medium 7.1 10.5 7.2 10.9
Low 3.8 4.0 4.0 3.8
Location
Metropolitan 95.0 94.6 0.80 95.1 94.1 0.53
Other 5.0 5.4 4.9 5.9
Inpatient admissions (annual %) 6.8 3.3 0.01 5.9 7.1 0.48
Emergency room visits (annual %) 17.8 11.2 0.005 16.7 13.6 0.24
Physician office visits per year 6.5 5.9 0.07 6.3 6.3 0.91
Acute hospital beds per 1000 2.0 2.0 0.94 2.0 2.0 0.96
Primary care physicians per 100,000 67.2 67.3 0.93 67.0 68.3 0.27
Pre period (months) 11.2 10.7 0.007 11.0 10.9 0.75
Post period (months) 22.6 28.9 < 0.0001 22.6 27.6 < 0.0001
Charlson Comorbidity Index (CCI) 1.5 1.2 < 0.0001 1.4 1.4 0.36
CCI = 0 4.7 17.8 < 0.0001 7.9 7.7 0.90
CCI = 1 62.9 58.3 0.18 61.7 60.5 0.71
CCI ‡ 2 32.4 23.9 0.008 30.3 31.9 0.64
Psychiatric Diagnostic Group 0.2 0.2 0.27 0.2 0.2 0.65
No (score = 0) 84.9 81.9 0.24 84.3 85.7 0.56
Yes (score ‡ 1) 15.1 18.1 0.24 15.7 14.3 0.56
BCBS, Blue Cross Blue Shield; UHC, UnitedHealthcare; VBID, value-based insurance design
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significant differences over the follow-up period compared
to nonparticipants.
As with participants with diabetes, employer-paid phar-
macy expenditures significantly increased for participants
with hypertension (P< 0.0001) but, with the shorter follow-
up time period, medical expenditures also increased, al-
though not significantly (P= 0.34), as shown in Table 4.
Overall, the adjusted DID for combined medical and phar-
macy expenditures for participants and nonparticipants with
hypertension were not statistically significant (P = 0.11).
Pharmaceutical co-payments for participants with hyper-
tension decreased significantly by $8.90 per month or about
$110 per year (P £ 0.0001; data not shown). Annualized
adjusted differences for inpatient admissions and emergency
room utilization rates for participants with hypertension
indicated significant increases in both inpatient and emer-
gency room use over the follow-up period compared to
nonparticipants.
Discussion
The VBID plus health/disease coaching program design
implemented by this large employer leveraged information
suggested by the scientific literature that VBID programs are
more effective if program designs include coaching op-
tions.2,6,10 The present evaluation included several meth-
odological improvements to more reliably evaluate medical
and pharmacy utilization and expenditure outcomes. Eligi-
ble nonparticipants within the same company were used
as controls for this study design. This assured equivalent
Table 2. Baseline Characteristics of Hypertension VBID Participants and Nonparticipants
Before and After Propensity Score Weighting
Unweighted Propensity Score Weighted
Participant Nonparticipant Participant Nonparticipant
Mean or % Mean or % P value Mean or % Mean or % P value
Hypertension 2674 580 2674 580
Age (average age) 49.8 49.3 0.20 49.8 50.1 0.46
18–34 5.2 4.8 0.41 5.2 5.6 0.44
35–44 24.1 24.8 23.8 20.6
45–54 38.0 40.9 38.5 39.9
55 + 32.8 29.5 32.5 34.0
Sex
Female 31.4 42.8 < 0.0001 33.5 34.3 0.68
Male 68.6 57.2 66.6 65.7
Relationship
Employee 87.2 65.5 < 0.0001 82.6 81.2 0.40
Spouse 12.8 34.5 17.4 18.8
Health plan
BCBS 29.9 28.5 0.72 29.8 27.2 0.03
UHC 58.2 58.8 57.4 56.0
Other 11.9 12.8 12.8 16.8
Income
High 71.4 74.7 0.47 72.1 72.4 0.63
Upper Medium 12.8 12.1 12.6 14.1
Lower Medium 6.9 5.2 6.6 6.3
Low 2.8 2.4 2.7 2.6
Missing 6.1 5.7 6.1 4.7
Location
Metropolitan 95.6 96.2 0.48 95.6 95.6 0.94
Other 4.5 3.8 4.4 4.5
Inpatient admissions (annual %) 5.0 4.8 0.88 5.3 6.9 0.15
Emergency room visits (annual %) 15.6 15.3 0.86 15.8 18.5 0.11
Physician office visits per year 5.7 5.6 0.55 5.7 6.0 0.32
Acute care hospital beds per 1000 2.0 1.9 0.002 2.0 2.0 0.50
Primary care physicians per 100,000 68.2 69.8 0.08 68.4 68.9 0.56
Pre period (months) 11.5 11.2 0.003 11.4 11.5 0.76
Post period (months) 13.3 18.2 < 0.0001 13.3 19.1 < 0.0001
Charlson Comorbidity Index (CCI) 0.67 0.45 < 0.0001 0.65 0.73 0.08
CCI = 0 58.7 69.7 < 0.0001 59.9 55.4 0.04
CCI = 1 25.5 21.0 0.02 25.1 25.7 0.79
CCI ‡ 2 15.8 9.3 < 0.0001 15.0 19.0 0.02
Psychiatric Diagnostic Group 0.25 0.35 0.001 0.26 0.30 0.14
No (score = 0) 80.3 74.0 0.001 79.2 77.3 0.31
Yes (score ‡ 1) 19.8 26.0 0.001 20.8 22.7 0.31
BCBS, Blue Cross Blue Shield; UHC, UnitedHealthcare; VBID, value-based insurance design
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corporate benefits, health messaging, and optional health
management programs across both participants and controls.
The take-up rates for the VBID programs were very high, a
tribute to the recruitment and referral strategies of the
health/disease coaches and to the perceived value of the
VBID co-payment reduction design. Some VBID designs
minimize pharmacy co-payment reductions with lowered
coinsurance rates rather than elimination of some co-pay-
ments (especially for high-value generic medications).2,7
Rather than population-based evaluations, the research team
documented VBID participation with documented enroll-
ment dates and payment verification by the PBM provider.
Use of propensity score weighting and subsequent regres-
sion adjustments, and exclusion of outliers and maternity
cases improved on previous methodologies utilized in the
measurement of health care expenditure trends over time.21
Key outcomes for VBID programs generally focus on
changes in patient pharmacy co-payments (substantially
decreased) and significantly improved medication adher-
ence. MPRs for both participants with diabetes and hyper-
tension increased about 3 to 4 percentage points—in the
general range of what is reported in the literature for other
VBID studies.2,4–6,8,9 Some VBID programs have indicated
that time is required to build on medication adherence rates
or that medication adherence improvements may not be
sustainable.1,2,9 The present program showed relatively
consistent MPRs over the respective follow-up periods,
likely a benefit of the coaching interactions integrated into
the program.
However, nonparticipants in both programs, decreased
medication adherence by about 10 percentage points. This
increase in nonadherence over time among nonparticipants
has been noted by other researchers.5,6,8,9 Thus, the medica-
tion adherence advantages of VBID participants relative to
nonparticipants apparently includes not only increased med-
ication adherence with decreased pharmacy co-payments
but also functions to prevent pharmacy discontinuation (ie,
increasing rates of nonadherence over time).5 The overall
gain in medication adherence for participants with diabetes or
hypertension, relative to controls, was about 14 percentage
points.
Medical services utilization including both inpatient ad-
missions and emergency room visits was minimally im-
pacted. It is possible that longer term studies are needed in
order to demonstrate a program impact of reduced emer-
gency room visits or inpatient admissions among employee/
spouse populations. In this evaluation, participants with di-
abetes with an average of about 2 years of follow-up showed
changes in utilization that were not statistically significant
after adjustments for covariates. In contrast, the hyper-
tension program with about 1 year of follow-up showed a
short-term increase in medical utilization likely because of
increased focus on management of the condition. Perhaps
longer (eg, 3–5 year) follow-ups may be needed—although,
to date, only 1-,3,6,8,10,11,13 2-,4,9 or 3-year1,2,7 VBID studies
have been published.
VBID programs are used to improve quality of care
by encouraging improved adherence to prescription drug
medications. Although such programs are often evaluated
for cost efficiency, profitability is not necessarily a re-
quirement for success. For example, several VBID studies
FIG. 1. Unadjusted descriptive pre to post MPRs for di-
abetes and hypertension VBID participants and nonpartici-
pants.
Diabetes: N = 814 participants/276 nonparticipants.
Hypertension: N = 2674 participants/580 nonparticipants.
MPR, medication possession ratio; VBID, value-based in-
surance design
Table 3. Differences in MPRs, Medical Utilization Rates, and Combined Medical and Pharmacy
Expenditures for Diabetes VBID Participants Relative to Nonparticipants
Diabetes VBID
Combined Medical
Expenditures (Paid) MPRs
Inpatient
Admissions
Emergency
Room Visits
DID (PMPM) P value DID* P value DID* P value DID* P value
Descriptive Unadjusted - $17.30 0.74 13.6 < 0.0001 - 2.7 0.10 - 6.7 0.01
Descriptive Weighted by PS - $91.30 0.08 13.4 < 0.0001 1.9 0.34 - 2.5 0.40
Medical Expenditures $29.00 0.58
Pharmacy Expenditures - $120.30 < 0.0001
Regression Adjusted Weighted by PS - $75.13 0.48 14.1 < 0.0001 2.4 0.24 - 1.0 0.74
N= 814 participants and 276 nonparticipants.
*DID percentage point difference in MPRs or annualized medical services utilization rates.
DID, difference in difference; MPR, medication possession ratio; PMPM, per member per month; PS, propensity score; VBID, value-
based insurance design
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considered successful have concluded that their programs
were cost neutral.1,2,6,10,12,21 Although the diabetes program
did show some medical cost savings (about $350 per
member per year), that was not enough savings to offset the
increased pharmacy expenditures by the employer (about
$1445 per member per year). The average age of partici-
pants was about 50 years in a relatively highly educated
workforce with multiple options for other health manage-
ment programs. In this environment, it may take more time
for the investment in additional medication consumption to
provide a documented return on that investment. In their
recent review of published VBID studies Lee et al21 con-
cluded that, given the various program designs, study time
lines, and analytic methodologies, the programs do not in-
crease or decrease medical cost trends. The present study
would fall within those parameters in that combined medical
and pharmacy expenditures changes (ie, increases) associ-
ated with the programs were not statistically significant.
Limitations
Propensity score weighting and regression adjustments
were utilized to account for differences between participant
and nonparticipant populations in order to evaluate the im-
pact of the VBID program on health care utilization and
expenditures for pharmaceuticals and health care spending.
However, additional unmeasured differences may still exist
between the populations (eg, attitudes toward health, en-
gagement levels). The research team did not have infor-
mation on the disease stages but, with an average age of
about 50, most individuals likely would be in the early
stages of their disease. This justifies the program focus on
prevention and improved management but will necessitate
longer term studies with additional years of follow-up to
demonstrate potential positive cost outcomes. 1,2,6,12,21,22
Using nonparticipants from the same company who were
eligible but chose not to enroll in the VBID program ensured
that these individuals had the same benefits programs,
similar health messaging, and the advantages of the same
on-site and online health management programs. Further-
more, the research team qualified the study population
(participants and nonparticipants) as chronic pharmacy
utilizers by requiring at a minimum at least 2 prescriptions
pre and post to further ensure equivalent comparison
populations.
This VBID program design included health/disease
coaching and was integrated into a well-designed, multiyear
health management program targeting a younger, healthier
workforce. The combination of the VBID program with
coaching provided a highly effective initial take-up of the
program with immediate medication adherence improve-
ments. However, these results may not generalize to other
employer groups with different workforce characteristics
and/or limited options for health management programming.
Conclusions
This newly implemented VBID program significantly
reduced pharmacy co-payments for participants and signif-
icantly increased medication adherence for both participants
with diabetes and hypertension while nonparticipants had a
significant medication adherence drop-off. Inpatient admis-
sions and emergency room utilization were not significantly
impacted. Significantly increased pharmacy expenditures
(both diabetes and hypertension medications) were partially
offset by medical savings (for diabetes) but not sufficiently
to be considered cost neutral.
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